Cargando…
A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer
A key step in providing management/treatment options to men with suspected prostate cancer (PCa) is categorizing the risk in terms of the presence of benign, low-risk, intermediate-risk, or high-risk disease. Our novel modality brings new evidence, based on the long-known hallmark characteristic of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914539/ https://www.ncbi.nlm.nih.gov/pubmed/36766529 http://dx.doi.org/10.3390/diagnostics13030424 |
_version_ | 1784885689167380480 |
---|---|
author | Weksler, Meir Simon, Avi Lenkinski, Robert E. Landsman, Hagar Matzkin, Haim Mabjeesh, Nicola Leibovitch, Ilan |
author_facet | Weksler, Meir Simon, Avi Lenkinski, Robert E. Landsman, Hagar Matzkin, Haim Mabjeesh, Nicola Leibovitch, Ilan |
author_sort | Weksler, Meir |
collection | PubMed |
description | A key step in providing management/treatment options to men with suspected prostate cancer (PCa) is categorizing the risk in terms of the presence of benign, low-risk, intermediate-risk, or high-risk disease. Our novel modality brings new evidence, based on the long-known hallmark characteristic of PCa—decreased zinc (Zn), which is the most direct metabolic sign of malignancy and its aggressiveness. To date, this approach has not been adopted for clinical use for a number of reasons that are described in this article, and which have been addressed by our approach. Zn has to be measured on fresh samples, prior to fixating in formalin; therefore, samples have to be scanned during the biopsy session. As Zn depletion occurs in the glands where the tumors develop, estimation of the glands’ levels in the scanned tissue, along with their compactness, are essential for accurate diagnosis. Combined with the Zn depletion, this facilitates a reliable assessment of disease aggressiveness. Data gathered in the clinical study described here indicate that, in addition to improving the biopsy quality by real-time interactive guidance, a malignancy score can now be established for the entire prostate, allowing higher granularity personalized risk stratification and more decisive treatment decisions for all PCa patients. |
format | Online Article Text |
id | pubmed-9914539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99145392023-02-11 A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer Weksler, Meir Simon, Avi Lenkinski, Robert E. Landsman, Hagar Matzkin, Haim Mabjeesh, Nicola Leibovitch, Ilan Diagnostics (Basel) Article A key step in providing management/treatment options to men with suspected prostate cancer (PCa) is categorizing the risk in terms of the presence of benign, low-risk, intermediate-risk, or high-risk disease. Our novel modality brings new evidence, based on the long-known hallmark characteristic of PCa—decreased zinc (Zn), which is the most direct metabolic sign of malignancy and its aggressiveness. To date, this approach has not been adopted for clinical use for a number of reasons that are described in this article, and which have been addressed by our approach. Zn has to be measured on fresh samples, prior to fixating in formalin; therefore, samples have to be scanned during the biopsy session. As Zn depletion occurs in the glands where the tumors develop, estimation of the glands’ levels in the scanned tissue, along with their compactness, are essential for accurate diagnosis. Combined with the Zn depletion, this facilitates a reliable assessment of disease aggressiveness. Data gathered in the clinical study described here indicate that, in addition to improving the biopsy quality by real-time interactive guidance, a malignancy score can now be established for the entire prostate, allowing higher granularity personalized risk stratification and more decisive treatment decisions for all PCa patients. MDPI 2023-01-24 /pmc/articles/PMC9914539/ /pubmed/36766529 http://dx.doi.org/10.3390/diagnostics13030424 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Weksler, Meir Simon, Avi Lenkinski, Robert E. Landsman, Hagar Matzkin, Haim Mabjeesh, Nicola Leibovitch, Ilan A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer |
title | A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer |
title_full | A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer |
title_fullStr | A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer |
title_full_unstemmed | A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer |
title_short | A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer |
title_sort | novel modality enables new evidence-based individual risk stratification that can potentially lead to decisive management and treatment decisions in prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914539/ https://www.ncbi.nlm.nih.gov/pubmed/36766529 http://dx.doi.org/10.3390/diagnostics13030424 |
work_keys_str_mv | AT wekslermeir anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT simonavi anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT lenkinskiroberte anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT landsmanhagar anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT matzkinhaim anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT mabjeeshnicola anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT leibovitchilan anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT wekslermeir novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT simonavi novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT lenkinskiroberte novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT landsmanhagar novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT matzkinhaim novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT mabjeeshnicola novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer AT leibovitchilan novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer |